Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edap TMSFOCL -2.25%56 3-Year EBITDA Growth Rate is -303.50% as of Mar. 2026. GuruFocus rates FOCL with a GF Score™ of 56/100 and a GF Value™ of $4.45 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 105 Medical Distribution companies, Edap TMS ranks worse than 99.05% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -303.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Edap TMS was 114.40% per year. The lowest was -303.50% per year. And the median was 13.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Edap TMS 3-Year EBITDA Growth Rate Related Terms
FOCL vs ACH, YI, COSM: 3-Year EBITDA Growth Rate Comparison
For the Medical Distribution subindustry, Edap TMS's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edap TMS 3-Year EBITDA Growth Rate vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Edap TMS's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Edap TMS's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -303.50% mean?
Edap TMS (FOCL) has a 3-Year EBITDA Growth Rate of -303.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Edap TMS and its competitors. According to the industry distribution chart, Edap TMS ranks #104 out of 105 companies in the Medical Distribution industry, placing it in the top 99%.
Is Edap TMS's 3-Year EBITDA Growth Rate too high?
Edap TMS's current 3-Year EBITDA Growth Rate is -303.50%. Based on the distribution chart, Edap TMS ranks #104 out of 105 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Edap TMS has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Edap TMS's 3-Year EBITDA Growth Rate compare to ACH and YI?
According to the Medical Distribution industry distribution chart, Edap TMS ranks #104 out of 105 companies for 3-Year EBITDA Growth Rate. This places Edap TMS in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 5.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Distribution company?
The median 3-Year EBITDA Growth Rate among Medical Distribution companies is 5.40, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Edap TMS and its competitors. For the Medical Distribution industry, the median 3-Year EBITDA Growth Rate is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edap TMS's current 3-Year EBITDA Growth Rate is -303.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edap TMS stock overvalued right now?
Based on GuruFocus' analysis, Edap TMS (FOCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.45, compared to a current price of $6.08 — trading 36.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is -303.50%. Edap TMS's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Edap TMS (FOCL), the current 3-Year EBITDA Growth Rate is -303.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edap TMS (FOCL) Overvalued in 2026?
Based on GuruFocus' analysis, Edap TMS stock appears to be overvalued.
The current stock price of $6.08 is trading 36.6% above its estimated GF Value™ of $4.45.
GuruFocus considers Edap TMS to be Significantly Overvalued.
Key valuation signals for FOCL:
3-Year EBITDA Growth Rate: -303.50%
GF Value™: $4.45 vs. price of $6.08 (36.6% above fair value)
No single metric tells the full story. See the FOCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.
56GF Score
Get the complete analysis for FOCL
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FOCL has been successfully added to your 
